| Crohn Disease

Hulio vs Rayos

Side-by-side clinical, coverage, and cost comparison for crohn disease.

Deep comparison between: Hulio vs Rayos with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsRayos has a higher rate of injection site reactions vs Hulio based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Rayos but not Hulio, including UnitedHealthcare

Category

Hulio

Rayos

At A Glance

RouteSC injection

FrequencyEvery 1-2 weeks

ClassTNF-alpha inhibitor

RouteOral

FrequencyDaily

ClassCorticosteroid

Indications

Rheumatoid Arthritis
Juvenile arthritis
Arthritis, Psoriatic
Ankylosing spondylitis
Crohn Disease
Ulcerative Colitis
Psoriasis vulgaris
Hidradenitis Suppurativa
Uveitis

Dermatitis, Atopic
Allergic rhinitis (disorder)
Serum Sickness
Dermatitis Herpetiformis
Contact Dermatitis
Exfoliative dermatitis
Mycosis Fungoides
Pemphigus
Erythema Multiforme
Congenital Adrenal Hyperplasia
Hypercalcemia
thyroiditis; nonsuppurative
Adrenal gland hypofunction
Crohn Disease
Ulcerative Colitis
Autoimmune hemolytic anemia
Anemia, Diamond-Blackfan
Immune thrombocytopenic purpura
Pure Red-Cell Aplasia
Acute leukemia
Lymphoma, Non-Hodgkin
Multiple Sclerosis
Cerebral Edema
Ophthalmia, Sympathetic
Uveitis
Chronic Obstructive Airway Disease
Aspergillosis, Allergic Bronchopulmonary
Aspiration pneumonitis
Asthma
Tuberculosis
Extrinsic allergic alveolitis
Bronchiolitis Obliterans Organizing Pneumonia
Idiopathic eosinophilic pneumonitis
Idiopathic Pulmonary Fibrosis
Pneumonia, Lipid
Sarcoidosis
Nephrotic Syndrome
Primary gout
Ankylosing spondylitis
Dermatomyositis
Polymyalgia Rheumatica
Arthritis, Psoriatic
Polychondritis, Relapsing
Rheumatoid Arthritis
Sjogren's Syndrome
Lupus Erythematosus, Systemic
Vasculitis
Trichinellosis
Tuberculosis, Meningeal

Dosing

Rheumatoid Arthritis, Arthritis, Psoriatic, Ankylosing spondylitis 40 mg SC every other week; some Rheumatoid Arthritis patients not taking concomitant MTX may benefit from 40 mg every week or 80 mg every other week.

Juvenile arthritis Patients 2 years of age and older: 15 kg to <30 kg: 20 mg SC every other week; >=30 kg: 40 mg SC every other week.

Crohn Disease Adults: 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; pediatric patients >=6 years weighing 17 kg to <40 kg: 80 mg Day 1, 40 mg Day 15, 20 mg every other week; weighing >=40 kg: 160 mg Day 1, 80 mg Day 15, 40 mg every other week.

Ulcerative Colitis 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every other week starting Day 29; discontinue if no clinical remission by Day 57.

Psoriasis vulgaris, Uveitis 80 mg SC initial dose, followed by 40 mg every other week starting one week after the initial dose.

Hidradenitis Suppurativa 160 mg SC on Day 1, 80 mg on Day 15, then 40 mg every week or 80 mg every other week starting Day 29.

All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.

Contraindications

—

Known hypersensitivity to prednisone or any excipient

Drug Interactions

1223View drug interactions

1287View drug interactions

Adverse Reactions

Most common (>=5%) Injection site reactions, upper respiratory infection, headache, rash, sinusitis, nausea, accidental injury, urinary tract infection, abdominal pain, flu syndrome, hyperlipidemia, back pain, hypercholesterolemia, hypertension, hematuria, alkaline phosphatase increased.

Serious Serious infections (pneumonia, septic arthritis, cellulitis, diverticulitis, pyelonephritis), tuberculosis, opportunistic infections, malignancies, hepatitis B virus reactivation, neurologic reactions, hematological reactions, heart failure, autoimmunity, severe hepatic reactions including acute liver failure.

Postmarketing Diverticulitis, large bowel perforations, pancreatitis, pyrexia, liver failure, hepatitis, sarcoidosis, Merkel Cell Carcinoma, demyelinating disorders, cerebrovascular accident, interstitial lung disease, pulmonary embolism, Stevens Johnson Syndrome, cutaneous vasculitis, erythema multiforme, new or worsening psoriasis, alopecia, lichenoid skin reaction, systemic vasculitis, deep vein thrombosis.

Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain

Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure

Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone

Pharmacology

Adalimumab-fkjp is a recombinant human IgG1 monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors, reducing inflammatory and immune responses in conditions including RA, JIA, PsA, AS, CD, UC, Ps, HS, and UV.

Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Hulio